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Abstract
Background: This study evaluated the effect of omeprazole or pantoprazole on platelet reactivity in non-ST-
segment elevation acute coronary syndrome (NSTE-ACS) patients receiving clopidogrel.
Methods: Consecutive patients with NSTE-ACS (n = 620) from general hospital of Shenyang Military Command
were randomized to the omeprazole or pantoprazole (20 mg/d) group (1:1), and received routine dual antiplatelet
treatment. Patients’ reversion rate of adenosine diphosphate-induced platelet aggregation (ADP-PA) was assessed at
baseline, 12 to 24 h after administration of medication, and after 72 h of percutaneous coronary intervention (PCI).
The primary endpoint of the study was platelet reactivity assessed with ADP-PA at 30 days after PCI. Adverse events
(AEs) were recorded for 30-day and 180-day follow-up periods.
Results: There were no significant differences between both the groups in platelet response to clopidogrel at 12–24 h
after drug administration (54.09% ± 18.90% vs 51.62% ± 19.85%, P = 0.12), 72 h after PCI (52.15% ± 19.45% vs 49.66% ±
20.05%, P = 0.18), and 30 days after PCI (50.44% ± 14.54% vs 48.52% ± 15.08%, P = 0.17). The rate of AEs did not differ
significantly between groups during the 30-day (15.2% vs 14.8%, P = 0.91) and 180-day (16.5% vs 14.5%, P = 0.50)
follow-up periods after PCI.
Conclusions: The addition of omeprazole or pantoprazole to clopidogrel did not restrict the effect of platelet
aggregation by reducing the conversion of clopidogrel. Compared with clopidogrel alone, pantoprazole-clopidogrel
and omeprazole-clopidogrel combinations did not increase the incidence of adverse clinical events during 30-day and
180-day follow-up periods after PCI.
Trial registration: The study is registered in the National Institutes of Health website with identifier NCT01735227.
Registered 14 November 2012.
Keywords: Omeprazole, Pantoprazole, Clopidogrel, Platelet response, Non-ST-segment elevation acute coronary
syndrome
* Correspondence: wxiaozeng@163.com
Department of Cardiology, General Hospital of Shenyang Military Region,
Shenyang 110840, China
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gu et al. Military Medical Research  (2016) 3:38 
DOI 10.1186/s40779-016-0107-0
Background
Numerous clinical trials and physician practices have
shown dual antiplatelet therapy (DAPT) to play a vital
role in the treatment of patients with acute coronary
syndrome (ACS) undergoing percutaneous coronary
implantation (PCI) [1]. Although DAPT can effectively
inhibit coronary stent thrombosis in patients with is-
chemic heart disease, reduce the incidence of major
adverse cardiovascular events (MACE), and control the
rate of readmission, thus greatly improving patients’
quality of life, it can also increase the risk of gastrointes-
tinal complications. Therefore, in 2010, the American
College of Cardiology Foundation, the American College
of Gastroenterology, and the American Heart Association
recommended that proton pump inhibitors (PPIs) be pre-
scribed to patients undergoing DAPT to decrease the risk
of gastrointestinal bleeding [2–5]. However, medications
metabolized by cytochrome P450 (CYP450), such as PPIs,
have been shown to decrease the effectiveness of clopido-
grel, and observational studies have suggested that PPIs
might restrict the effect of platelet aggregation by reducing
the conversion of clopidogrel into its active form through
competitive inhibition of the CYP2C19 isoenzyme, based
on pharmacodynamic data. In addition, several reports
have shown that concomitant use of clopidogrel and
PPIs is associated with an increased risk of adverse
outcomes compared with the use of clopidogrel alone
[6–10]. However, Dunn et al. [11] showed no signifi-
cant difference in the number of adverse events (AEs)
following PCI in patients with and without PPI. While
omeprazole has been associated with reduced clopido-
grel efficacy, as assessed by the platelet reactivity index
vasoactive stimulated phosphoprotein, new PPIs such as
pantoprazole and esomeprazole have been shown to have
no effect on biological response to clopidogrel [12]. Because
many PPIs are metabolized to varying degrees by CYP2C19,
the reported negative omeprazole-clopidogrel drug inter-
action may not be caused by a class effect [13, 14].
PPIs are usually prescribed to patients undergoing dual
antiplatelet therapy to decrease the risk of gastrointestinal
bleeding. However, there has been an increased incidence
of MACE because of the interaction of PPIs and clopido-
grel. Therefore, this study was conducted to evaluate the
effect of omeprazole or pantoprazole on platelet reactivity
in non-ST-segment elevation acute coronary syndrome
(NSTE-ACS) patients receiving clopidogrel.
Methods
Study design and population
This prospective, randomized controlled clinical trial
(NCT01735227) was conducted at department of cardi-
ology, General Hospital of Shenyang Military Region to
compare the influence of omeprazole or pantoprazole on
the antiplatelet effect of clopidogrel in patients undergoing
PCI for NSTE-ACS. In our study, we defined NSTE-ACS
as unstable angina (UA) and NSTEMI because all STEMI
patients received immediate emergency PCI if the clinical
symptoms were compatible with acute myocardial ische-
mia within 12 h before admission. Patients aged 18 to
75 years were eligible to be enrolled if they had coronary
artery disease and opted to undergo PCI. Eligible patients
were randomly assigned to 2 groups that received either
omeprazole or pantoprazole (in a 1:1 ratio; random enve-
lope provided by the CRO company). The major exclusion
criteria included the use of glycoprotein IIb/IIIa inhibitors
within 24 h before enrollment or use of cilostazol within
7 days before enrollment, contraindication to DAPT, and
a history of severe systemic bleeding or greatly increased
risk of bleeding. Patients were also excluded if they had
New York Heart Association grade III or IV cardiac func-
tion, PCI or coronary artery bypass grafting (CABG)
within the past year, persistent atrial fibrillation requiring
long-term warfarin, or prior use of a PPI or clopidogrel.
Patients with serious liver or kidney dysfunction were also
excluded. The design of the study is depicted in Fig. 1.
For 80% power to detect the noninferiority of
omeprazole-clopidogrel or pantoprazole-clopidogrel to
clopidogrel alone, a sample size of 295 patients were
assigned to each of the omeprazole and pantoprazole
groups in a 1:1 ratio. Patients were required to achieve a
two-sided significance level of 0.05. Taking into account
an attrition rate of about 5%–10%, at least 620 patients
were enrolled in our study.
Study protocol
The study was approved by the ethics committee of
General Hospital of Shenyang Military Region. The
study was performed in accordance with ethical princi-
ples that have their origin in the Declaration of Helsinki
and are consistent with ICH/Good Clinical Practice. All
patients provided written informed consent before en-
rollment. All patients received a loading dose of 300 mg
each of clopidogrel and aspirin, and were randomized to
take 20 mg daily of either omeprazole (Losec MUPS;
AstraZeneca, London, UK) or pantoprazole (Tecta;
Takeda Pharmaceuticals International GmbH, Konstanz,
Germany) and received routine dual antiplatelet treat-
ment (aspirin 300 mg and clopidogrel 75 mg daily). PPI
therapy was resumed in both groups following comple-
tion of the primary endpoint of the study.
Blood samples (two 3.6 ml tubes) were taken to meas-
ure the reversion rate of ADP-PA, which was defined as
20 μmol/L adenosine diphosphate-induced platelet ag-
gregation by light transmittance aggregometry (LTA)
before randomization, 12 to 24 h after drug administra-
tion, and 72 h after PCI. The upper, platelet-rich plasma
layer was prepared by centrifuging blood samples for
12 min; the remaining platelet-poor plasma was obtained
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by centrifuging for 15 min for use as a blank control. Plate-
let aggregation rate was determined with an AggRAM®
eight-channel Advanced Modular System for Platelet
Aggregation Ristocetin Cofactor (Helena Laboratories,
Beaumont, TX, USA) by a skilled technician. An assess-
ment of platelet reactivity by LTA was scheduled for all
enrolled patients 30 days after PCI. Results were used in
the primary-endpoint evaluation.
Study endpoints
The primary endpoint of the study was platelet reactivity
of 20 μmol/L ADP-PA by LTA 30 days after PCI. The
secondary endpoints were clinical events during the 30-
day and 180-day follow-up periods after PCI, which
included stent thrombosis, MACE (cardiac death, non-
fatal myocardial infarction, or ischemic symptom-driven
target-vessel revascularization [TVR] or non-TVR), all-
cause death, thrombolysis in myocardial infarction (TIMI)
bleeding events, stroke, and adverse drug reactions. Stent
thrombosis was defined according to the Academic
Research Consortium criteria, and only definite stent
thrombosis was counted [15]. Myocardial infarction was
defined as a creatine kinase myocardial band level that
was more than twice the upper limit of normal range and
either symptoms consistent with acute myocardial infarc-
tion or electrocardiographic changes in at least two con-
tiguous leads (pathologic Q waves 0.04 s in duration or
persistent ST-segment elevation or ST-segment depres-
sion > 0.1 mV). TVR included intervention because of
recurrence in any part of the original vessel. Bleeding
events were divided into major or minor bleeding on the
basis of thrombolysis in TIMI bleeding classification as
follows: major bleeding = intracranial hemorrhage or a
>5 g/dl decrease in hemoglobin concentration or a >15%
absolute decrease in hematocrit; moderate bleeding =
observed blood loss (a > 4 g/dl decrease in hemoglobin
concentration or a > 12% decrease in hematocrit);
minor bleeding = no observed blood loss (a > 3 g/dl
decrease in hemoglobin concentration or a > 10% de-
crease in hematocrit) [16]. Stroke was defined as per-
sistent loss of neurological function developing after
primary PCI and an acute lesion identified with mag-
netic resonance imaging. Adverse drug reactions in our
study included reactions to aspirin, clopidogrel, ni-
trates, and statins.
All patients had a follow-up evaluation at a clinic visit
or via telephone contact 30 and 180 days following PCI.
The China Cardiovascular Research Foundation (CCRF),
an independent clinical research organization, was re-
sponsible for database management, safety monitoring,
and evaluation of AEs. All AEs were adjudicated by a
blinded, independent clinical-events committee. The
CCRF reviewed the data periodically to identify any
potential safety issues.
Statistical analysis
This study used intention-to-treat analysis data sets for
statistical analysis. Comparisons among normally distrib-
uted continuous variables are presented as mean ± stand-
ard deviation and were compared using Student’s unpaired
t-test. Categorical variables are expressed as frequencies
and percentages. Comparisons between groups were made
using the Chi-square or Fisher exact test for categorical
variables and nonparametric statistical testing (Mann-
Whitney U-test) for continuous variables. Values of P <
0.05 were considered statistically significant. All analyses
were performed with the IBM SPSS Statistics for Windows,
Version 21.0 (IBM Corp, Armonk, NY, USA).
Fig. 1 Patient flowchart
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Results
From October 2012 to September 2013, a total of 620
patients with NSTE-ACS were enrolled from general
hospital of Shenyang military region. Thirteen patients
did not undergo angiography and were excluded. The
remaining 607 patients were included, with 303 patients
allocated to the omeprazole group and 304 to the panto-
prazole group. All patients completed 30 and 180 days
follow-up periods after PCI. All groups were generally
well balanced with regard to baseline demographic,
clinical, and procedural characteristics. Baseline and pro-
cedural characteristics of the study patients are shown in
Tables 1 and 2. Of those 607 patients, 602 (99.8%)
underwent coronary angiography after an oral loading
dose of aspirin 300 mg and clopidogrel 300 mg on ad-
mission. Successful PCI, which was defined as recovery
of coronary flow to TIMI grade 2 to 3 and residual sten-
osis <50%, was achieved in all patients. Two patients
died during hospitalization: one from stent thrombosis
and the other because of traumatic brain injury. There
were no differences between the omeprazole and panto-
prazole groups in platelet response to clopidogrel on
admission, 12 to 24 h after drug administration, and
72 h and 30 days after PCI (Fig. 2).
There were no significant differences between the two
groups in coronary angiography clinical data (Table 3),
and the 30-day and 180-day follow-up rates were 100%.
During the 30-day follow-up period, there was one case
of stent thrombosis in the pantoprazole group and none
in the omeprazole group, but the difference was not sig-
nificant. There were no significant between-group differ-
ences in rates of MACE. No major or minor bleeding
occurred in either group, and the rates of minimal
bleeding, which occurred in both groups, did not differ
significantly between the groups. Although one patient
died from traumatic brain injury in the omeprazole
Table 1 Baseline patient characteristics
Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Age (year) 59.15 ± 8.75 58.76 ± 8.50 0.58
Male [n (%)] 209 (69.0) 215 (70.7) 0.66
Cardiovascular risk factors
BMI (kg/m2) 25.57 ± 3.86 25.54 ± 3.43 0.92
Hypertension [n (%)] 199 (65.7) 186 (61.2) 0.27
Dyslipidemia [n (%)] 135 (44.6) 125 (41.1) 0.41
Diabetes mellitus [n (%)] 84 (27.7) 82 (27.0) 0.86
Active smoking [n (%)] 170 (56.1) 171 (56.3) 1.00
Previous myocardial infarction [n (%)] 48 (15.8) 46 (15.1) 0.82
Previous transient ischemic attack/stroke [n (%)] 27 (8.9) 27 (8.9) 1.00
Final clinical diagnosis [n (%)]
UA 262 (84.3) 264 (86.8) 0.90
NSTEMI 42 (13.9) 39 (12.8) 0.72
Laboratory parameters
WBC (×1012/L) 7.01 ± 1.85 6.91 ± 1.74 0.48
RBC (×109/L) 6.04 ± 0.34 4.52 ± 0.55 0.32
PLT (×1012/L) 211.16 ± 51.24 210.42 ± 51.89 0.86
Hb (g/L) 140.66 ± 15.19 141.24 ± 13.87 0.67
Creatinine (mg/dl) 71.73 ± 23.13 69.77 ± 22.95 0.27
CRP (mmol/L) 3.73 ± 6.47 4.82 ± 17.54 0.59
TNT (ng/ml) 0.08 ± 0.32 0.07 ± 0.31 0.62
Blood glucose (mmol/L) 6.40 ± 2.46 6.75 ± 3.39 0.21
Total cholesterol (mmol/L) 3.88 ± 1.05 3.86 ± 0.99 0.82
Total triglycerides (mmol/L) 1.97 ± 1.32 1.92 ± 1.42 0.95
Low-density lipoprotein cholesterol (mmol/L) 2.18 ± 0.95 2.14 ± 0.87 0.56
High-density lipoprotein cholesterol (mmol/L) 1.09 ± 0.72 1.11 ± 0.80 0.80
Baseline ADP-PA (%) 60.00 ± 20.87 57.50 ± 19.73 0.13
BMI Body mass index, UA Unstable angina, NSTEMI Non-ST segment elevation myocardial infarction, WBC White blood cell, RBC Red blood cell, PLT Platelet, Hb
Hemoglobin, CRP C-reactive protein, ADP-PA Adenosine diphosphate-induced platelet aggregation
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group, there was no significant difference between the
groups in all-cause death. No patient in either group
experienced stroke. There was no significant difference
in the rate of adverse drug reactions between the
omeprazole and pantoprazole groups. AEs for the two
groups during the 30-day follow-up period are shown
in Table 4 and Fig. 3.
During the 180-day follow-up period, there was no stent
thrombosis in either group. One major and three minor
bleeding events occurred in the pantoprazole group, but
there was no significant difference in the rate of minimal
bleeding between the groups. There was no significant
association of either intervention with all-cause death.
One patient in the omeprazole group died of lung cancer
and one patient in the pantoprazole group died of acute
brainstem hemorrhage (Table 5 and Fig. 4).
Discussion
Clopidogrel combined with aspirin in patients undergo-
ing PCI has been recommended because of its ability to
reduce cardiovascular events. It is well known that
gastrointestinal hemorrhage is the most common serious
bleeding complication of antiplatelet therapy, especially
in ACS patients. Therefore, PPIs are often prescribed to
prevent gastrointestinal tract bleeding during DAPT [17].
Recent studies, however, have suggested that PPIs might
reduce the antiplatelet effect of clopidogrel through inhib-
ition of hepatic CYP2C19 [18–20]. Clopidogrel is a prodrug
that requires hepatic CYP450-dependent biotransformation
into an active metabolite, which irreversibly blocks the
P2Y12 ADP receptor [21, 22]. The genotype of this enzyme
has been divided into three groups: rapid extensive metabo-
lizers, intermediate metabolizers, and poor metabolizers.
There are genetically interethnic differences in the fre-
quencies of poor metabolizers of CYP2C19: 2.5% in
white Americans, 2.0% in African Americans, 3.5% in
white Europeans, and 19.8% in the Chinese-Han popu-
lation. Because of the much greater prevalence of
CYP2C19 loss-of-function alleles in Asians than in
other populations, the influence of drug interaction
might be more apparent in Asian people [23]. A nation-
wide population study to investigate the influences of
concomitant use of clopidogrel and PPIs would be
necessary to elucidate CYP2C19 polymorphisms. A
Taiwanese population-based study has reported that the
concomitant use of clopidogrel and PPIs is associated
with an increased risk of rehospitalization and mortality
in patients undergoing PCI. Thus, prior studies have
suggested that an attenuation of the antiplatelet effect
of clopidogrel by PPIs could lead to adverse clinical out-
comes by decreasing the efficacy of clopidogrel. Previous
reports have demonstrated that concomitant use of PPI
and clopidogrel after PCI was associated with an increased
risk of rehospitalization and mortality, and higher rates of
Table 2 Procedural characteristic during hospitalization
Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Systolic blood pressure (mmHg) 140.01 ± 22.16 138.86 ± 18.36 0.55
Diastolic blood pressure (mmHg) 79.81 ± 13.88 80.05 ± 11.11 0.84
Left ventricular ejection fraction (%) 62.5 ± 11.2 63.7 ± 14.7 0.30
Medications at discharge [n (%)]
Statin 297 (98.0) 299 (98.4) 0.77
ACE inhibitors 160 (53.0) 143 (47.0) 0.17
Angiotensin receptor blocker 86 (28.4) 93 (30.7) 0.59
Beta-blockers 226 (74.6) 244 (80.3) 0.10
Calcium-channel blockers 77 (25.4) 79 (26.0) 0.93
Nitrate 274 (90.4) 268 (88.2) 0.43
Diuretics 35 (11.6) 33 (10.9) 0.80
Glycoprotein IIb/IIIa antagonists 32 (14.0) 22 (9.5) 0.15
Fig. 2 Changes in ADP-PA between the two groups of patients
Gu et al. Military Medical Research  (2016) 3:38 Page 5 of 9
Table 3 Analysis of coronary angiography
Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Target coronary vessel [n (%)]
Single-vessel 84 (29.2) 94 (32.3) 0.42
Multivessel 206 (71.5) 197 (67.7) 0.32
Localization of culprit lesion [n (%)]
Left main coronary artery 40 (13.2) 38 (12.5) 0.81
Left anterior descending artery 219 (72.3) 225 (74.0) 0.65
Left circumflex artery 142 (46.9) 135 (44.4) 0.57
Right coronary artery 164 (54.1) 158 (52.0) 0.63
Other artery 113 (37.3) 91 (29.9) 0.06
Baseline blood flow in the culprit vessel [n (%)]
TIMI 0 47 (15.7) 35 (11.6) 0.16
TIMI 1 18 (6.0) 17 (5.6) 0.86
TIMI 2 33 (11.0) 27 (8.9) 0.42
TIMI 3 202 (67.3) 223 (73.8) 0.09
Final blood flow in the culprit vessel [n (%)]
TIMI 0 8 (2.7) 11 (3.6) 0.64
TIMI 3 281 (93.7) 285 (94.4) 0.73
Characteristics of coronary angiography 0.23
Number of implanted stents (n) 1.29 ± 1.63 1.18 ± 1.07 0.23
Average stent diameter (mm) 2.24 ± 1.42 2.22 ± 1.44 0.81
Average length of implanted stents (mm) 18.62 ± 12.50 18.55 ± 12.98 0.94
Contrast media [n (%)]
Isotonic 25 (8.4) 27 (9.0) 0.85
Non-isotonic 274 (91.6) 273 (91.0) 0.85
Median contrast agent dose (ml) 220.20 ± 134.97 205.73 ± 118.83 0.16
Table 4 AEs during 30-day follow-up
Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Stent thrombosis [n (%)] 0 1 (0.3) 1.00
MACEs [n (%)] 7 (2.3) 5 (1.6) 0.58
Cardiac death 1 (0.3) 0 0.50
Myocardial infarction 0 0 —
Ischemic symptoms driven target vessel revascularization 1 (0.3) 0 0.50
Non-target vessel revascularization 5 (1.7) 5 (1.6) 1.00
Recurrent angina [n (%)] 19 (6.3) 12 (3.9) 0.20
All-cause death [n (%)] 1 (0.3)a 0 0.50
TIMI bleeding events [n (%)]
Major 0 0 —
Moderate 0 0 —
Minor 4 (1.3) 8 (2.6) 0.38
Stroke [n (%)] 0 0 —
Adverse drug reactions [n (%)] 23 (7.6) 29 (9.5) 0.47
AEs [n (%)] 46 (15.2) 45 (14.8) 0.91
aOne patient died due to brain injury in the omeprazole group
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cardiovascular events and increased risk of adverse out-
comes have been shown in patients undergoing treatment
with PPI-clopidogrel combination compared with clopido-
grel alone [9].
In contrast, Ray et al. reported that concomitant use of
clopidogrel with a PPI did not increase the incidence of
serious cardiovascular disease but was associated with a
50% reduction in the incidence of hospitalizations for
gastrointestinal bleeding. Several other studies have also
reported that PPI use is not associated with an increased
risk of cardiovascular events or mortality in patients tak-
ing clopidogrel [3–10, 12].
Kwok et al. [24] reviewed 23 studies involving 93,278
patients, and their meta-analysis of 13 of these studies
showed no significant association between PPI use and
overall mortality. In the latest study, the COGENT trial,
3761 patients with an ACS were randomized at the time
of PCI to take clopidogrel and omeprazole or clopidogrel
alone, and no evidence of any adverse clinical interaction
was observed [3]. The results showed that the majority
of patients who were discharged on a PPI were pre-
scribed lansoprazole (77.7%), followed by omeprazole
(17.8%) and rabeprazole (4.5%). Kenngott et al. [25] indi-
cated that the clopidogrel-PPI interaction does not seem
to be a PPI class effect, and that rabeprazole did not
interfere with the clopidogrel effect in a subject with a
clear omeprazole-clopidogrel interaction. Other studies
have suggested that the omeprazole-clopidogrel inter-
action was stronger than that of clopidogrel with other
PPIs [3, 6]. However, in vivo data show that lansoprazole
has the potential to have the same or greater potency
than omeprazole. In addition to clinical factors such as
drug interactions, genetic factors, including polymor-
phisms of the CYP system, are important [14, 17]. The
CYP2C19 polymorphism in particular appears to play a
key role in both clopidogrel and PPI metabolisms. It
could be that reduction in the functional alleles of
CYP2C19 is associated with lower levels of the active
metabolite of clopidogrel, greater levels of platelet re-
activity, and a greater rate of adverse clinical outcomes
in patients receiving clopidogrel. The COGENT trial is
the only available controlled randomized study address-
ing the clinical relationship between PPIs and clopido-
grel, and no evidence of any adverse clinical interaction
was reported. However, 94% of the population in the
COGENT trial was Caucasian, and the expected preva-
lence of CYP2C19 loss-of-function alleles was 2–3% [3].
The relative risk of gastrointestinal bleeding in patients
receiving DAPT and the effectiveness of PPIs in prevent-
ing such bleeding are obviously critical to any decision
to initiate concomitant therapy with a PPI and clopido-
grel. Evidence has shown that PPIs are effective in
Fig. 3 The rate of adverse clinical events in the two groups during
30-day follow-up




group (n = 304)
P value
Stent thrombosis [n (%)] 0 0 —
MACEs [n (%)] 8 (2.6) 7 (2.3) 0.80
Cardiac death 1 (0.3) 0 0.50




3 (1.0) 1 (0.3) 0.37
Non-target vessel
revascularization
6 (2.0) 6 (2.0) 1.00
Recurrent angina [n (%)] 30 (9.9) 24 (7.9) 0.40
All-cause death [n (%)] 1 (0.3)a 1 (0.3)b 1.00
TIMI bleeding
evens [n (%)]
15 (5.0) 19 (6.3) 0.60
Major 0 1 (0.3) 1.00
Moderate 0 3 (1.0) 0.25
Minor 16 (5.3) 14 (4.6) 0.71
Stroke [n (%)] 1 (0.3) 0 0.50
Adverse drug
reactions [n (%)]
17 (5.6) 19 (6.3) 0.86
AEs [n (%)] 50 (16.5) 44 (14.5) 0.50
aOne patient died due to lung cancer in the omeprazole group
bOne patient died due to acute brainstem hemorrhage in the
pantoprazole group
Fig. 4 The rate of AEs in both the groups during 180-day follow-up
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preventing gastrointestinal bleeding in patients receiving
antiplatelet therapy, including aspirin or clopidogrel, but
the clinical outcomes of various studies have thus far
shown conflicting results [3–6].
Therefore, coronary heart disease patients who receive
clopidogrel therapy can have different individual responses.
We used ADP 20 μmol/L as an inducer and evaluated
platelet function by LTA. LTA is the classic method for
testing platelet function. In 2010, the POPular study
by Breet et al. [26], compared the correlations between
incidence of clinical events and six methods of platelet
function measurement: VerifyNow®, LTA, Plateletworks™,
DiaMed Impact-R, PFA-100®, and Innovance® PFA P2Y.
Their results showed that VerifyNow® (13.3% vs 5.7%, P <
0.001), LTA (11.7% vs 6.0%, P < 0.001), and Plateletworks®
(12.5% vs 6.1%, P = 0.005) were better correlated with
clinical results than the other methods. However, there is
still no stronger predictive value than area under the
curve (0.61–0.63).
The platelet function test results for individual DAPT is
currently a research focus, possibly because on-treatment
platelet reactivity is not a modifiable risk factor for throm-
botic events after PCI. On the other hand, thrombosis is
not only associated with antiplatelet therapy, but also in-
fluenced by many environmental and genetic factors, such
as atherosclerotic plaque instability; heart, kidney, or other
vital organ dysfunction; or sluggish blood flow.
Although in vitro studies have suggested a possible
effect and several retrospective analyses were supportive
of an adverse clinical outcomes, recent data from pro-
spective controlled trials do not support an adverse cardio-
vascular outcome, nor do they show a clear relationship
between PPI use and adverse outcomes. Therefore, this
topic remains controversial. Careful risk-benefit assess-
ment is required before prescribing PPIs to individual
patients receiving DAPT, as indicated in the statement by
the US Food and Drug Administration.
Safety is a concern in antiplatelet therapy, but in the
present study, there were no significant differences be-
tween the groups in the rates of muscle pain, liver func-
tion test results, gastrointestinal disorders, or incidence
of edema or rash during the 30-day and 180-day follow-
up periods.
Our trial had several limitations. Firstly, a major limi-
tation of the study was that CYP2C19 polymorphisms
were not considered; therefore, a future study to investi-
gate the influences of concomitant use of clopidogrel
with different PPIs in different ethnicities would be
necessary. Secondly, the follow-up period was short and
the sample relatively small, and so a longer follow-up
period and larger sample size will be necessary to ex-
plore the effect of PPIs on clopidogrel. Thirdly, we used
LTA to test platelet aggregation in our study because of
storage time, beside detection just as VerifyNow® may
reduce detection error. Finally, as with any prospective
study, a causal relation cannot be confirmed, nor can
confounding by unknown or unmeasured factors be
entirely excluded. Because this was not a blinded study,
there was a potential for observational bias.
Conclusion
In conclusion, the study results suggest that combination
therapy with omeprazole or pantoprazole and clopidogrel
does not restrict ADP-induced platelet aggregation. There
was no apparent association between clinical events and
clopidogrel-omeprazole or clopidogrel-pantoprazole com-
bination in NSTE-ACS patients. The clinical impact of
this strategy needs to be confirmed by long-term follow-
up outcome studies.
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